Florida-based biotechnology company Enveric Biosciences has announced the issuance of a new patent by the US Patent and Trademark Office for its drug candidate, EB-002.
The patent covers methods of treatment for various neurological disorders, including sleep disorders, depression, substance-related disorders, and headaches, using EB-002 and related compounds.
EB-002 is Enveric's psilocin prodrug being developed initially for anxiety. The company claims the new patent expands the intellectual property protection for EB-002, increasing its potential to be used in additional neurological conditions and serve a broader range of patient populations.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.